{"mainPropery":{"diseaseId":2356,"diseaseName":"Follicular lymphoma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/2356/follicular-lymphoma","synonyms":["Lymphoma, follicular"],"synonyms-with-source":[{"name":"Lymphoma, follicular"}],"identifiers":[{"identifierType":"OMIM","identifierId":"151430"},{"identifierType":"ORPHANET","identifierId":"545"},{"identifierType":"UMLS","identifierId":"C0024301"}]},"diseaseCategories":[{"diseaseTypeId":12,"diseaseTypeName":"Blood Diseases","source":"Orphanet"},{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/151430' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=(follicular%5BTitle%5D+AND+lymphoma%5BTitle%5D)+AND+(%22loattrfull+text%22%5Bsb%5D+AND+%22loattrfree+full+text%22%5Bsb%5D+AND+hasabstract%5Btext%5D+AND+%222004%2F08%2F14%22%5BPDat%5D+%3A+%222009%2F08%2F12%22%5BPDat%5D+AND+%22humans%22%5BMeSH+Terms%5D+AND+English%5Blang%5D)' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Follicular lymphoma. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Follicular+lymphoma%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Follicular lymphoma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/203268-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=545' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1543,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=428287' target='_blank'>National Cancer Institute</a> provides the most current information on cancer for patients, health professionals, and the general public.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1545,"resourceId":2173,"resourceName":"Merck Manual","descriptionText":"The <a href='http://www.merck.com/mmpe/sec11/ch143/ch143c.html?qt=Follicular%20lymphoma&alt=sh' target='_blank'>Merck Manuals Online Medical Library</a> provides information on this condition for patients and caregivers.&nbsp;","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:0050873' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/non-hodgkin-s-lymphoma' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":0,"dateModified":"0001-01-01T00:00:00"},"basicQuestions":[],"references":[],"relatedDiseases":[{"relatedDiseaseId":11955,"relatedDiseaseName":"Lymphoma","relation":"Parent","isRare":false,"hasGardPage":false}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":13043,"phenoTypeName":"Fever","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13815,"phenoTypeName":"Lymphoma","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":11806,"phenoTypeName":"Mediastinal lymphadenopathy","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":12206,"phenoTypeName":"Night sweats","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":5059,"phenoTypeName":"Weight loss","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13704,"phenoTypeName":"Fatigue","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3886,"phenoTypeName":"Splenomegaly","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13763,"phenoTypeName":"Abnormality of the peritoneum","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8283,"phenoTypeName":"Lymphedema","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8738,"phenoTypeName":"Meningitis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13873,"phenoTypeName":"Pleural effusion","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":959,"phenoTypeName":"Skin nodule","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4893,"phenoTypeName":"B-cell lymphoma","percentRanges":"-"},{"phenoTypeId":8123,"phenoTypeName":"Somatic mutation","percentRanges":"-"}],"medicalProducts":[{"productId":693,"genericName":"Copanlisib","tradeName":"Aliqopa","tradeLink":"https://www.hcp.aliqopa-us.com/","manufacturer":"","sponsor":"Bayer US LLC","indication":"For the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/aliqopa","medlinePlusLink":""},{"productId":736,"genericName":"PI3K-delta and PI3K-gamma inhibitor","tradeName":"Duvelisib","tradeLink":"https://www.verastem.com/pipeline/duvelisib-pi3k-delta-pi3k-gamma-inhibitor/","manufacturer":"","sponsor":"Verastem, Inc.","indication":"September 2018, PI3K-delta and PI3K-gamma inhibitor (Duvelisib) was approved for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or follicular lymphoma after at least two prior therapies.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/duvelisib","medlinePlusLink":""},{"productId":640,"genericName":"Obinutuzumab","tradeName":"Gazyva","tradeLink":"http://www.gazyva.com/","manufacturer":"","sponsor":"Genentech, Inc.","indication":"Indicated for the treatment of patients with follicular\r\nlymphoma (FL) who relapsed after, or are refractory to, a rituximab containing regimen. Also treatment of patients achieving at least a partial remission as well as the treatment of adult patients with previously untreated stage II bulky, II or IV follicular lymphoma.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/gazyva","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a614012.html"},{"productId":686,"genericName":"Rituximab and hyaluronidase human","tradeName":"Rituxan Hycela","tradeLink":"https://www.rituxanhycela.com/patient.html","manufacturer":"","sponsor":"Genentech, Inc.","indication":"Treatment of adult patients with relapsed or refractory, follicular lymphoma as a single agent, previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy, non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/rituxan%20hycela","medlinePlusLink":""}],"EncodedName":"Follicular_lymphoma"}